Business / Finance RSS Feed - Business / Finance

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011. [More]

HeartWare revenues for fiscal 2011 increase to $82.8 million

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced revenue of $23.1 million for the fourth quarter ended December 31, 2011, as compared to $20.9 million for the fourth quarter of 2010. [More]

ICON fourth quarter net revenues increase 5% to $242.6 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year and fourth quarter ended December 31, 2011. [More]
BioCryst fourth quarter revenues decrease to $5.2 million

BioCryst fourth quarter revenues decrease to $5.2 million

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2011. [More]

Dey Pharma to change company name to Mylan Specialty

Mylan Inc. today announced that it plans to change the name of its fully integrated branded specialty pharmaceutical business from Dey Pharma to Mylan Specialty. [More]

Medworxx announces expansion into the U.S.

On the heels of a year marking 36% growth in hospital beds served, Medworxx Inc., a leader in clinical patient flow solutions, announced today its expansion into the USA. [More]

Teva fourth quarter net revenues increase 28% to $5.7 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2011. [More]

Microsoft, GE announce several developments for planned joint venture

General Electric Co. (GE), through its healthcare IT business, and Microsoft Corp. today announced several developments for their planned 50-50 joint venture, including the intention to demonstrate future product capabilities at HIMSS12, the year's largest healthcare IT trade show, later this month. [More]
Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam. [More]

Bristol-Myers Squibb acquires Inhibitex

Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share. [More]